Analyst Swayampakula Ramakanth of H.C. Wainwright reiterated a Buy rating on Humacyte, retaining the price target of $3.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including promising clinical data and the potential for increased adoption of Humacyte’s Acellular Tissue Engineered Vessel (ATEV). The recent 24-month data from the V007 study showed that ATEV significantly outperformed the standard of care in female hemodialysis patients, indicating a successful outcome for the ongoing V012 study. This is particularly important as the study addresses an unmet need in women with smaller blood vessels who are more likely to be catheter-dependent.
Furthermore, the growing body of evidence supporting ATEV’s long-term durability and low infection rates across various indications suggests a strong potential for wider clinical adoption. The absence of immune rejection and other complications further strengthens the case for ATEV. Financially, the valuation is supported by a risk-adjusted net present value analysis, leading to a 12-month price target of $3.00, reflecting confidence in Humacyte’s future growth prospects.
Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Nanobiotix, and Personalis. According to TipRanks, Ramakanth has an average return of 16.8% and a 41.40% success rate on recommended stocks.
In another report released on November 24, TD Cowen also maintained a Buy rating on the stock with a $3.50 price target.